Pantover 40 mg/vial (IV Injection)

40 mg vial: ৳ 85.00

Medicine Details

Category Details
Generic Pantoprazole sodium
Company Veritas pharmaceuticals ltd
Also available as
Pantover 20 mg tablet

ProductTitle

  • Pantover 40 mg/vial Injection

Categories

  • Medicine
  • Proton Pump Inhibitor
  • Gastric Acid Reducer

Description

  • Pantover is indicated for the suppression of acid secretion for various therapeutic benefits such as peptic ulcer diseases, gastroesophageal reflux diseases, ulcers induced by NSAIDs, eradication of Helicobacter pylori, and Zollinger-Ellison Syndrome.
  • It is a proton pump inhibitor that covalently binds to the H+/K+ ATPase enzyme system, leading to the suppression of gastric acid production.
  • The oral dosage for various conditions ranges from 20-80 mg daily, with specific recommendations for benign gastric ulcer, gastroesophageal reflux disease, duodenal ulcer, prophylaxis of NSAID-associated gastric or duodenal ulcer, and Zollinger-Ellison Syndrome.
  • IV Injection dosage is also specified for duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, prevention of rebleeding in peptic ulcer, prophylaxis of acid aspiration, and long-term management of Zollinger-Ellison Syndrome.
  • It has no significant drug interactions observed in clinical studies and is contraindicated in patients with known hypersensitivity to any of its components.
  • Common side effects include headache and diarrhea, with rare side effects like abdominal pain, flatulence, rash, insomnia, and hyperglycemia.
  • It is classified as US FDA Pregnancy Category B, and caution is advised during pregnancy and lactation.
  • Precautions should be taken to avoid splitting, chewing, or crushing the tablet during long-term therapy of Pantover to prevent malabsorption of Vitamin B12 and the risk of osteoporosis-related disorders.
  • There are no known symptoms of overdosage in humans, and no specific therapy is recommended.
  • It should be stored in a dry place, away from light and heat, and out of the reach of children.

Indications

  • Suppression of acid secretion for therapeutic benefits
  • Peptic ulcer diseases
  • Gastroesophageal reflux diseases
  • Ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs)
  • Eradication of Helicobacter pylori (in combination with antibiotics)
  • Zollinger-Ellison Syndrome

Pharmacology

  • Proton pump inhibitor
  • Suppresses the final step in gastric acid production
  • Covalently binds to the H+/K+ ATPase enzyme system

DosageAndAdministration

  • Oral and IV Injection dosage information for various conditions
  • Specific dosages for different ailments and recommended durations of treatment

Interaction

  • No significant drug interactions observed in clinical studies

Contraindications

  • Contraindicated in patients with known hypersensitivity to any of the components

SideEffects

  • Common side effects include headache and diarrhea
  • Rare side effects may include abdominal pain, flatulence, rash, insomnia, and hyperglycemia

PregnancyAndLactation

  • US FDA Pregnancy Category B
  • Caution advised during pregnancy and lactation
  • Excreted in human milk

PrecautionsAndWarnings

  • Tablets should not be split, chewed, or crushed
  • Long-term therapy may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis-related disorders

OverdoseEffects

  • No known symptoms of overdosage in humans
  • Pantover is highly protein-bound and not readily dialyzable

StorageConditions

  • Store in a dry place, away from light and heat
  • Keep out of the reach of children

ChemicalStructure

  • Molecular Formula: C16H15F2N3O4S

AdministrationRoute

  • Oral
  • IV Injection

DrugClass

  • Proton Pump Inhibitor

Reconstitution

  • Detailed directions for reconstitution and administration of IV injection

PregnancyCategory

  • US FDA Pregnancy Category B

Dosage

  • Specific dosages for different ailments and recommended treatment durations

SideEffectsInformation

  • Information about common and rare side effects

ModeOfAction

  • Suppression of the final step in gastric acid production
  • Irrespective of the stimulus, inhibition of both basal and stimulated gastric acid secretion, persisting longer than 24 hours

PharmacologicalProperties

  • Proton pump inhibitor
  • Covalently binds to the H+/K+ ATPase enzyme system at the surface of the gastric parietal cell

TherapyInfo

  • Indicated therapy for peptic ulcers, GERD, ulcers induced by NSAIDs, eradication of Helicobacter pylori, and Zollinger-Ellison Syndrome

AdverseEffects

  • Headache and diarrhea as common side effects

CommonQuestions

  • Common questions and answers about Pantover 40 mg/vial Injection

Related Brands